MedPageToday -- ADELPHI, Md. -- An FDA advisory committee will meet here on Wednesday to discuss the fate of the weight-loss drug sibutramine (Meridia) in light of results from a six-year randomized clinical trial suggesting that the drug raises the risk of cardiovascular events.
